Our investments have contributed to the development of numerous marketed products. We take pride in having contributed to their success.
Antibiotic to treat acute bacterial skin and skin structure infections (ABSSSI) in both intravenous (IV) and oral formulation.
The first once-daily antibiotic to treat CABP and ABSSSI that is available in both an intravenous (IV) and oral formulation.
Roxadustat is a first-in-class, oral drug for the treatment of anemia in chronic kidney disease patients on dialysis.
ZEMDRI™ (plazomicin)—an antibiotic indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis.
Instruments and Research Tools
Andrew, the liquid handling robot designed to enhance the reproducibility and efficiency of the pipetting process.
Andrew+, the second generation liquid handling robot, can perform a wide range of complex experimental steps.
Pipette+, the first connected smart pipetting system for maximum experiment repeatability with the minimum of effort.
Diagnostics and Other Products
MagnetOs Putty is indicated for use as an osteoconductive and osteoinductive bone void filler in the skeletal system.
Nevisense is the world’s first objective diagnostic support tool for non-visual detection of malignant melanoma.
Omega Fund Management, LLC and its affiliates (collectively, “Omega”) only owns its own trademarks, with all other trademarks being the property of their respective owners. Nothing on this website should be construed as granting, by implication, estoppel, or otherwise, any license or right to use any trademark displayed on this website without the prior written consent of the trademark owner. Nothing on this website should be construed as promoting or recommending any of the drugs/products that are displayed on this website.